Research reveals the solution structure of Garvicin Q, a broad-spectrum bacteriocin targeting man-pts in specific bacteria, indicating unique antimicrobial properties.
Class IId bacteriocins are linear, unmodified antimicrobial peptides produced by Gram-positive bacteria, and often display potent, narrow-spectrum inhibition spectra. Garvicin Q (GarQ) is a class IId bacteriocin produced by the lactic acid bacterium Lactococcus garvieae. It stands out for its unusual broad-spectrum antimicrobial activity against various bacterial species, including Listeria monocytogenes, Pediococcus pentosaceus, Carnobacterium maltaromaticum, Enterococcus faecalis, and Lactococcus spp. Its protein target is the mannose phosphotransferase system (Man-PTS) of susceptible bacterial strains, though little is known about the precise molecular mechanism behind GarQ’s unusual broad spectrum of activity. In this work, 13C- and 15N-labelled GarQ was recombinantly produced using our previously described “sandwiched” protein expression system in Escherichia coli. We also developed a protocol to purify a uniformly labelled sample of the small ubiquitin-like modifier His6-SUMO, which is produced as a byproduct of the expression procedure. We demonstrated its use as a “free” protein standard for 3D NMR experiment calibrations. The GarQ solution structure was solved using triple-resonance nuclear magnetic resonance (NMR) spectroscopy and was compared with the structures of other Man-PTS-targeting bacteriocins. GarQ adopts a helix–hinge–helix fold, which is contrary to its structural predictions according to AlphaFold 3.
No takes yet. Share an insight, caveat, or question.
Mallett et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: